Free Trial
NASDAQ:ONCY

Oncolytics Biotech Q2 2025 Earnings Report

Oncolytics Biotech logo
$1.12 -0.09 (-7.08%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 0.00 (0.00%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncolytics Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncolytics Biotech Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Oncolytics Biotech Earnings Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Oncolytics Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email.

About Oncolytics Biotech

Oncolytics Biotech (NASDAQ:ONCY) is a clinical-stage biotechnology company dedicated to developing pelareorep, an oncolytic immunotherapy derived from a naturally occurring virus designed to target and kill cancer cells while stimulating the body’s immune response. The company’s primary research and development efforts focus on leveraging pelareorep as a platform technology, evaluating its potential both as a standalone treatment and in combination with established cancer therapies, including chemotherapy, targeted agents, and immuno-oncology drugs.

The company’s product pipeline centers on multiple Phase II and exploratory studies across a range of solid tumors. Key investigational indications include breast cancer, head and neck cancer, metastatic pancreatic cancer, and non–small cell lung cancer. By partnering with leading academic institutions and pharmaceutical collaborators, Oncolytics has broad access to patients and trial sites in North America, Europe, and the Asia-Pacific region, facilitating data collection on safety, efficacy, and mechanisms of action.

Founded in 1998 as a spin-out from the University of Calgary, Oncolytics has built a robust intellectual property portfolio and advanced its lead candidate through successive stages of clinical evaluation. The company operates research facilities in Calgary, Alberta, and maintains strategic partnerships to support development and commercialization activities. Its global footprint enables ongoing dialogue with regulators and key opinion leaders to expedite the development pathway for pelareorep.

Oncolytics is led by a seasoned management team with deep expertise in oncology drug development, virology, and regulatory affairs. Under the direction of Chief Executive Officer Lee Schrader, the company continues to expand its clinical trial network and engage with potential collaborators to optimize combination strategies. Oncolytics’ board and scientific advisors include individuals with extensive experience in biotechnology, pharmaceuticals, and academic medicine, positioning the company to advance its novel immunotherapeutic approach toward potential market approval.

View Oncolytics Biotech Profile

More Earnings Resources from MarketBeat